A Randomized Controlled Trial to Evaluate Allopurinol Versus Placebo on Left Ventricular Mass in Living Kidney Donors
Kidney360 · 2026-10 · 7 (10) · 2363-2371
DOI: 10.34067/kid.0000001313 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Kidney360, online erschienen am 03.08.2026. Verfasst von Nina Elisabeth Langberg und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Transplantation Medicine, Oslo University Hospital, Rikshospitalet, Oslo, Norway. Hauptthemen laut MEDLINE: Allopurinol, Living Donors, Kidney Transplantation, Nephrectomy. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Helse Sør-Øst RHF, Fondsstiftelsen, Norwegian renal Association.
Abstract (Originalsprache)
Key Points Donation of a kidney is regarded safe, although it may be associated with increased long-term cardiovascular risks. This is the first study to evaluate if allopurinol has any benefits on left ventricular mass, ambulatory BP, and insulin resistance in kidney donors. We found no clinically relevant positive impact of 9 months of allopurinol treatment on cardiovascular risk factors in living kidney donors.
Background
Living kidney donation is regarded safe, although recent studies raise concern on long-term cardiovascular risks, including left ventricular mass (LVM) and hypertension, resulting in higher cardiovascular mortality. Elevated uric acid has been associated with higher LVM. We therefore hypothesized that lowering uric acid can reduce LVM in living kidney donors.
Methods
The study was a single-center, phase 2b efficacy, 1:1 randomized, double-blind, placebo-controlled trial over 9 months.
Participants
( n =71) were healthy kidney donors aged 18+ years with eGFR >30 ml/min per 1.73 m 2 examined ≥6 months after donor nephrectomy. The intervention consisted of allopurinol 300 mg or placebo once daily for 9 months, and the main outcome was change in LVM from baseline to month 9 in the allopurinol group compared with placebo, evaluated by the use of cardiac magnetic resonance imaging.
Results
Uric acid levels were significantly lower in the allopurinol group ( P < 0.001). We found no significant differences between the changes in magnetic resonance imaging–estimated LVM between the treatment groups. The mean changes were −0.25 (±4.4) g in the allopurinol group and 1.04 (±4.2) g in the placebo group ( P = 0.25). There was no effect of allopurinol on BP ( P = 0.98) or indexes of insulin sensitivity ( P = 0.62). Adverse events occurred in 28 (39%) participants, 18 (70%) in the allopurinol group and ten (37%) in the placebo group. Three events were considered severe, all in the allopurinol group.
Conclusions
We found no effects on LVM, BP, or insulin sensitivity of 9 months of allopurinol treatment in living kidney donors, despite a significant effect on uric acid. Clinical Trial registry name and registration number: NCT03353298.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Transplantation Medicine, Oslo University Hospital, Rikshospitalet, Oslo, Norway.
- Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway.
- Division for Technology and Innovation, The Intervention Centre, Oslo University Hospital, Oslo, Norway.
- Department of Pharmacy, Section of Pharmacology and Pharmaceutical Biosciences, University of Oslo, Oslo, Norway.
ORCID-Profile: Nina Elisabeth Langberg, Trond Geir Jenssen, Einar Hopp, Anders Haugen, Anders Åsberg, Kåre I Birkeland, Anders Hartmann, Dag Olav Dahle
Förderung
- Helse Sør-Øst RHF
- Fondsstiftelsen
- Norwegian renal Association
- Agnete and Einar Magnessen/Gerd Stamnes and Erling Brodwalls fund
- Diabetesforbundet
Zitieren
APA
Langberg, N. E., Jenssen, T. G., Hopp, E., Haugen, A., Åsberg, A., Birkeland, K. I., Hartmann, A., & Dahle, D. O. (2026). A Randomized Controlled Trial to Evaluate Allopurinol Versus Placebo on Left Ventricular Mass in Living Kidney Donors. Kidney360, 7(10), 2363-2371. https://doi.org/10.34067/kid.0000001313
Vancouver
Langberg NE, Jenssen TG, Hopp E, Haugen A, Åsberg A, Birkeland KI, et al. A Randomized Controlled Trial to Evaluate Allopurinol Versus Placebo on Left Ventricular Mass in Living Kidney Donors. Kidney360. 2026;7(10):2363-2371. doi:10.34067/kid.0000001313
BibTeX
@article{Langberg2026,
author = {Langberg, Nina Elisabeth and Jenssen, Trond Geir and Hopp, Einar and Haugen, Anders and Åsberg, Anders and Birkeland, Kåre I and Hartmann, Anders and Dahle, Dag Olav},
title = {A Randomized Controlled Trial to Evaluate Allopurinol Versus Placebo on Left Ventricular Mass in Living Kidney Donors},
journal = {Kidney360},
year = {2026},
volume = {7},
number = {10},
pages = {2363--2371},
doi = {10.34067/kid.0000001313}
}
EUVIMED